Leading biopharmaceutical company Parexel International Corporation has opened offices in Chengdu and Guangzhou, China, to tap into the growing clinical development industry in the Asia Pacific region.

Parexel now has 17 offices in strategic biopharmaceutical centres within Asia Pacific.

Parexel International chairman and CEO Josef von Rickenbach said that China is expected to become the fifth-largest market this year, and will reach a value of approximately $47bn by 2013.

“A high prevalence of certain cancers, diabetes and other diseases in China can benefit from more extensive clinical research,” von Rickenbach said.

Parexel supports biopharmaceutical companies in accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality throughout Asia Pacific.